Certara Releases Environmental, Social and Governance Report

The report highlights a commitment to sustainability and corporate responsibilities.

RADNOR, Pa. – 2025 年 8 月 26 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development (MIDD), today announced that it has issued its 2025 environmental, social, and governance (ESG) report. The report outlines Certara’s approach to a responsible ESG framework across three strategic priorities: accelerating crucial medicines to patients, advancing scientific thought leadership and knowledge sharing, and increasing engagement with employees.

“Certara is transforming the way new medicines are discovered and developed helping bring treatments to patients faster and more efficiently,” said Daniel Corcoran, Senior Vice President and General Counsel. “We achieve this by delivering world-class biosimulation science and solutions to our clients, while also holding ourselves accountable to strong environmental, social, and governance practices. "

Certara 2025 ESG Report Highlights

Introduced 36 new software applications and upgrades with R&D investment of $37.1M (9% of revenue) in 2024.
Collaborated on more than 9,000 customer projects in the last decade.
Supported 300+ regulatory submissions in the past 5 years.
Total market-based greenhouse gas emissions were reduced by 21.51%*.
Fortune Best Workplaces in Biopharma 2022-2024 Great Place to Work® 2022-2025
Fortune Best Workplaces in the New York region 2024 (including PA, NJ, and CT)

Certara’s ESG Report is available here. The ESG Report was published in August 2025 and reflects data and information as of the respective dates set forth therein.

*Measures were captured and reported by an external sustainability advisor from 2023 to 2024. Emissions measures are Scopes 1 through 3, including direct, upstream and downstream measures.